Breakthrough in Treating Deadly Pediatric Brain Tumors

Promising progress has been made in the fight against some of the most aggressive pediatric brain tumors, offering new hope for affected children and their families as researchers report encouraging developments in treatment approaches and scientific understanding.

A Breakthrough in Childhood Brain Cancer Research

A recent international study has unveiled a surprising weakness in the most aggressive form of childhood brain cancer, the Group 3 medulloblastoma. This discovery, led by Dr. Olivier Ayrault at the Institut Curie and CNRS, shines new light on a disease that has long baffled researchers due to its complexity and poor prognosis.

The Lipid Storage Puzzle

Delving into an extensive collection of 384 tumor samples from the MB COMICS cohort—spanning contributions from France, Germany, the United States, and Canada—the research team employed a battery of five “omic” analyses. Their strategy involved integrating data from genomics, transcriptomics, and more, to dissect the unique biology underlying this lethal pediatric cancer. What emerged was quite unexpected: tumor cells from Group 3 displayed a distinctive lipid signature, especially marked when the well-known oncogene MYC was active.

This heightened MYC activity pushes tumor cells to accumulate fatty acids within lipid droplets. Far beyond simple energy reserves for mitochondria, these fat stores shield cells from oxidative stress and a specialized cell death mechanism called ferroptosis. “It’s the first time we’ve seen MYC directly promoting lipid buildup—revealing an Achilles’ heel in these particularly resistant tumors,” Dr. Ayrault explained.

DGAT1: A Potential Target for Therapy

Armed with this insight, researchers explored whether interfering with this metabolic adaptation could weaken the cancer. Preclinical trials provided compelling evidence: by inhibiting the enzyme DGAT1, which is central to forming these lipid droplets, they triggered toxic fat accumulation that tumor cells could not manage—leading to widespread cancer cell death.

Several factors explain this decision:

• DGAT1 inhibitors combined with standard chemotherapy increased treatment potency.
• The effect was most pronounced in tumors driven by MYC activation.

As Dr. Flavia Bernardi, lead author of the study published in Cancer Cell, remarked: “Adding DGAT1 inhibitors drastically amplified cell destruction in our preclinical models.”

A Ray of Hope for Incurable Cases

While clinical application remains on the horizon, and rigorous trials are yet to come, this newly identified metabolic weakness offers genuine hope for children facing currently untreatable forms of medulloblastoma. Should further studies confirm these findings, targeting DGAT1 could become a cornerstone in developing more precise treatments for one of pediatric oncology’s most daunting challenges.